Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer's disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32963242.
- Also identified by DOI 10.1038/s41467-020-18525-2 and PMC identifier 7509831.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Preventing aggregation of amyloid beta (Aβ) peptides is a promising strategy for the treatment of Alzheimer's disease (AD), and gold nanoparticles have previously been explored as a potential anti-Aβ therapeutics. Here we design and prepare 3.3 nm L- and D-glutathione stabilized gold nanoparticles (denoted as L3.3 and D3.3, respectively). Both chiral nanoparticles are able to inhibit aggregation of Aβ42 and cross the blood-brain barrier (BBB) following intravenous administration without noticeable toxicity. D3.3 possesses a larger binding affinity to Aβ42 and higher brain biodistribution compared with its enantiomer L3.3, giving rise to stronger inhibition of Aβ42 fibrillation and better rescue of behavioral impairments in AD model mice. This conjugation of a small nanoparticle with chiral recognition moiety provides a potential therapeutic approach for AD.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Gold
- Memory Disorders
- Metal Nanoparticles
- Peptide Fragments